Will Pricing For Gilead’s Sovaldi Set A Ceiling In HCV, Lead To A Price War?
Gilead’s wholesale acquisition cost of $1,000-a-day for Sovaldi met with immediate backlash, as well as foreboding comments from a leading PBM. Observers anticipate a possible pricing war between Gilead and other companies developing new regimens for HCV.
You may also be interested in...
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.